Panobinostat is a new histone deacetylase
inhibitor approved for
treatment
of advanced multiple myeloma.
In this study we compare its
effects
with doxorubicin which is already
used for trans-arterial chemoembolization
of hepatocellular carcinoma. Methods: anti-proliferative
and pro-apoptotic effects of panobinostat
and doxorubicin are tested by
measuring
cell viability, P53, pd1 expression
and cell cycle analysis in
HepG2
cells cultured in suitable media
and incubated with both drugs for
24
hours. Results:
Panobinostat was
found
to highly significantly induce apoptosis via increasing expression
of both P53 and pd1 and decrease
cell viability and mitosis more than
doxorubicin. Conclusion: These results
suggest that panobinostat may
be
a potent alternative to doxorubicin
for
treatment of hepatocellular carcinoma.